iBio Inc Newsroom

IBio Initiated at Buy by Chardan Capital

IBio Initiated at Buy by Chardan Capital

Dow JonesMay 28 18:59

IBio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/28/2024 121.24% Chardan Capital → $5 Initiates Coverage On → Buy 02/16/2023 — JMP Securities Downgrade

BenzingaMay 28 18:44

Ibio Inc: Chardan Capital Markets launches report with a buy rating; target price is $5

Ibio Inc: Chardan Capital Markets launches report with a buy rating; target price is $5

Zhitong FinanceMay 28 17:48

Express News | Ibio Inc : Chardan Capital Markets Initiates Coverage With Buy Rating; Target Price $5

BreakingsMay 28 17:48

Chardan Research Starts IBio With Buy Rating, $5 Price Target

Chardan Research Starts iBio With Buy Rating, $5 Price Target.

MT NewswiresMay 28 17:43

US and Europe speed up procurement of bird flu vaccine to deal with potential pandemic threat

The United States and Europe are taking steps to purchase or produce H5N1 avian influenza vaccines to protect at-risk poultry and dairy farm workers, vets, and laboratory technicians.

Zhitong FinanceMay 27 15:36

Avian flu cases spur retail investors to buy vaccine stocks

The increase in cases of avian influenza triggered investors to rush to buy vaccine stocks, and the stock prices of companies such as CureVac, Novavax, and Moderna soared. Experts recommend investing cautiously, as the development of the epidemic is uncertain.

FX168May 23 06:44

IBio Reports Q3 Results

Seeking AlphaMay 14 05:12

iBio Inc | 10-Q: Quarterly report

SEC announcementMay 14 04:22 · Announcements

IBio Q3 EPS $(0.71) Up From $(9.53) YoY

iBio (AMEX:IBIO) reported quarterly losses of $(0.71) per share. This is a 92.55 percent increase over losses of $(9.53) per share from the same period last year.

BenzingaMay 14 04:13

IBio 3Q Rev $0 >IBIO

IBio 3Q Rev $0 >IBIO

Dow JonesMay 14 04:06

Press Release: IBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update -- Strengthened cash position with investment by healthcare specialist investors -- Expanding into c

Dow JonesMay 14 04:05

The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...

① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.

cls.cnMay 10 16:52

IBio Files Prospectus Relates To Resale From Time To Time Of Up To 10.6M Shares Of Common Stock By Selling Stockholders

IBio Files Prospectus Relates To Resale From Time To Time Of Up To 10.6M Shares Of Common Stock By Selling Stockholders

BenzingaApr 17 04:14

IBio Inc. Raises $15M in Private Placement and Issues Warrants

TipRanksApr 2 04:53

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO

BenzingaMar 29 20:06

IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers

Seeking AlphaMar 28 22:01

Top Midday Gainers

iBio's (IBIO) shares were up 211% amid heavy trading Wednesday, a day after the company said it signed a securities purchase agreement for a private investment in public equity financing with expected

MT NewswiresMar 28 01:49

SMR, GCTS and GSIW Among Mid-day Movers

Seeking AlphaMar 28 01:22

IBio Climbs After AI-led Drug Discovery Deal

Seeking AlphaMar 28 00:00